Lab´s profitability was affected by extraordinary expenses related to the relocation to its new industrial complex
The main driver of growth was the launch of new products, offsetting an unusual drop in the sale of anti-flu products
Its PC plant start-up, and eventually the OTC plant as well, would result in improved profitability going forward
You can read this report by subscribing to a Starter or Pro plan today.
Already have an account? Log in
This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument.
This publication is not intended for distribution to, or use by, any person or entity in any jurisdiction in any country where such distribution or use would be contrary to law or regulation, or which would subject Tellimer to any registration requirement within such jurisdiction or country.This research is produced by a third party. The Tellimer team has had no editorial input into the content of the note.